Metabolic dysfunction-associated steatohepatitis

Researchers are testing whether lanifibranor, a drug for fatty liver disease, can improve blood sugar control in adults with NASH and type 2 diabetes. They are also studying whether combining lanifibranor with empagliflozin, a diabetes medication, works better than lanifibranor a…

This phase 2 trial tests whether a natural vitamin E supplement called tocotrienol can slow the worsening of end-stage liver disease. Seventy adults with stable but advanced liver disease (MELD score 8–17) will take either tocotrienol or a placebo twice daily for three years. The…

This early-stage trial tests an investigational drug called MWN105, given as an injection under the skin, in healthy Chinese volunteers aged 18 to 45. The study aims to check the drug's safety, how the body processes it, and whether it triggers an immune response. Researchers wil…

This phase 2 trial is testing whether an experimental drug called HTD1801 can reduce liver fat and improve blood sugar control in adults who have both nonalcoholic steatohepatitis (NASH) and type 2 diabetes. Participants receive either HTD1801 or a placebo for 18 weeks, and resea…

This study tests a new drug called HM15211 in 215 adults with NASH, a liver condition that can lead to scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver inflammation and scarring without making it worse…

This trial tests an experimental oral drug called HTD1801 in adults with nonalcoholic steatohepatitis (NASH), a serious liver condition, along with liver fibrosis and type 2 diabetes or prediabetes. Participants receive either HTD1801 or a placebo to see if the drug can improve l…

This study aims to find the most effective amount of exercise to reduce liver fat in people with NASH, a serious liver disease. Researchers will compare different exercise doses in 45 sedentary adults aged 18-69 with NASH and early-stage liver scarring. The goal is to provide cle…

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly…

This phase 2b trial tests whether efruxifermin, an experimental drug, can improve liver fibrosis (scarring) without worsening inflammation in people with compensated cirrhosis due to NASH. Participants receive either efruxifermin or a placebo for up to 96 weeks. The main goal is …

This study tests whether combining two diabetes drugs—semaglutide and empagliflozin—can reverse liver damage from NASH (a severe form of fatty liver disease) in people with type 2 diabetes. Participants will receive either the combo, empagliflozin alone, or a placebo for 48 weeks…

This study tested a drug called BOS-580 (efimosfermin) in 231 obese adults with or at risk for NASH, a serious fatty liver disease. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and side effects. The trial is now co…

This study tests an experimental drug called AZD2389 in people with liver fibrosis (scarring) and compensated cirrhosis (early-stage liver damage). The goal is to check the drug's safety and how the body handles it. About 40 adults with liver disease will receive either AZD2389 o…

This completed Phase 2 study tested whether a combination of two experimental drugs, K-877-ER and CSG452, can improve liver health in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The 228 participants received either the combination or a placebo. The main go…

This study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the drug could improve liver damage a…

This early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation us…

This study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by…

This study tested a weekly injection called pemvidutide in 212 adults with NASH, a serious liver condition linked to fat buildup. The goal was to see if the drug could reduce liver fat and scarring without worsening the disease. Participants received either the drug or a placebo …

This study tested different doses of vitamin E in 200 adults with nonalcoholic fatty liver disease (NAFLD) to find the best dose for improving liver health. Participants took vitamin E or a placebo for 24 weeks, and researchers measured changes in a key liver enzyme (ALT). The go…

This study tested whether taking phytosterols (plant-based supplements) for 3 months can improve liver health, cholesterol, and insulin levels in people with nonalcoholic fatty liver disease (NAFLD). 27 participants took either phytosterol pills or a placebo. Researchers measured…

This Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will s…

This study tests a medicine called survodutide in adults with overweight or obesity and a liver condition called NASH. Participants receive weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. The goal is to see if the drug reduces …

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …

This study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took either the drug combo or a placebo in cycles ove…

This study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…

This phase 2 trial tested elobixibat, a drug that blocks bile acid absorption in the gut, in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form NASH. Participants received either elobixibat or a placebo for 16 weeks. The main goal was to see if the dr…

This study looked at whether ketotifen, a medicine used for allergies, is safe and helpful for people with non-alcoholic fatty liver disease (NAFLD) who do not have cirrhosis. Sixty adults with NAFLD took part. The main goal was to see if ketotifen could improve liver scarring (f…

This study tested an experimental drug called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to see if the drug could help the liver heal (resolve NASH) without making scarring worse. Participants r…

This study tested a new drug called BIO89-100 (Pegozafermin) in 222 adults with NASH, a serious fatty liver disease with liver scarring. Participants received weekly injections of the drug or a placebo for about 6 months. The goal was to see if the drug could reduce liver inflamm…

This pilot study tested a drug called ibutamoren in 12 adults with nonalcoholic fatty liver disease (NAFLD). The goal was to see if it could lower fat in the liver. Participants took the drug for 6 months, and researchers measured liver fat using special MRI scans. The study was …

This phase 2 trial tested an oral drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a fatty liver disease that can lead to scarring and liver failure. The main goal was to see if the drug could reduce liver fat measured by MRI after 12 weeks compared t…

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…

This early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a type of liver disease. The study was completed and used a placebo for compa…

This phase 2 trial tested whether semaglutide (a diabetes drug) combined with cilofexor and firsocostat (two experimental liver drugs) can improve liver scarring and resolve NASH in people with cirrhosis. 457 participants with compensated cirrhosis due to NASH were randomly assig…

This study tested whether combining a new liver drug (NNC0194-0499) with semaglutide (a diabetes/weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 700 adults received weekly injections of either the drug combo, a different combo…

This study tested a monthly injection called AZD2693 in 220 adults with non-alcoholic steatohepatitis (NASH) and liver scarring, who carry a specific genetic risk factor. The goal was to see if the drug could reverse liver inflammation and scarring without making it worse. The tr…

This phase 2b trial tested whether saroglitazar magnesium can help people with nonalcoholic steatohepatitis (NASH) and liver fibrosis. 189 adults took either a 2 mg or 4 mg dose of the drug or a placebo daily for several months. The main goal was to see if the drug could resolve …

This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help …

This study tested an experimental drug called ARO-HSD in 50 healthy volunteers and people with NASH, a serious fatty liver disease. The main goal was to check safety and how the drug moves through the body. It's an early step to see if ARO-HSD might be a future treatment for NASH…

This study tested a drug called cotadutide in 54 adults with a type of fatty liver disease that includes liver scarring but not cirrhosis. Participants received either the drug or a placebo as a daily injection. The main goal was to check safety and tolerability, with results hel…

Researchers are testing the Liver Incyte system, an ultrasound device that measures how stiff the liver is, to see if it can tell healthy people apart from those with liver fibrosis or steatosis. The trial includes 140 adults, some healthy and some with a history of hepatitis C o…

This study looked at over 1,200 adults with metabolic fatty liver disease (MASLD) to see if a new digital test, called FibroNest Ph-FCS, can predict who will develop serious liver complications. The test uses computer analysis of standard liver biopsy images to measure scarring. …

This pilot study is testing whether a specialized MRI technique using hyperpolarized pyruvate can non-invasively detect metabolic changes in the liver that are linked to fatty liver disease. The study will include people with simple fatty liver (NAFL), those with the more advance…

This study investigates whether non-invasive imaging techniques—ultrasound and MRI—can accurately diagnose non-alcoholic steatohepatitis (NASH) and liver fibrosis in people with fatty liver disease. Currently, a liver biopsy is the gold standard, but it is invasive and carries ri…

This study tests a new ultrasound-based device called the Liver Incytes System to see if it can measure liver stiffness and fat as accurately as MRI and FibroScan. The device uses sound waves to create images of the liver, similar to a traditional ultrasound. Researchers are enro…

This study explores whether a simple breath test can detect early liver fibrosis in people with non-alcoholic steatohepatitis (NASH). Participants fast overnight, then drink a mixture of food-grade flavor compounds and provide breath samples over 90 minutes. The way the body proc…

This study tested a new ultrasound software that measures liver fat in children and teens aged 5 to 21 with or at risk for fatty liver disease. Researchers compared the ultrasound results to standard MRI scans to see if the ultrasound could accurately detect liver fat. If it work…

This study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information lik…

This study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …

This study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to standard methods like FibroScan and liver biopsy. The goal is to find a simpler, less …

This early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…

This study looked at liver fibrosis (scarring) in 127 HIV patients who had high liver enzymes while on antiretroviral therapy. Participants underwent tests like liver biopsy, ultrasound, and CT scans to measure liver damage. The goal was to understand how common and severe liver …

This study looked at whether a computer analysis of liver biopsy images (called FibroNest Ph-FCS) can predict future liver complications in people with a type of fatty liver disease called MASLD. Researchers reviewed medical records from 1,578 patients to see if the digital score…

This study looked at 315 HIV-positive adults to build models that predict fatty liver disease and liver scarring. Researchers used ultrasound and FibroScan tests to track liver changes over time. The goal was to better understand and identify liver problems early in people living…

This study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…

This study tested whether a pop-up alert in the electronic medical record could help doctors remember to refer patients with fatty liver disease (NASH) to a liver specialist. Thirty doctors from internal medicine, family medicine, and endocrinology took part. The goal was to see …

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This study looked at 10,000 older adults (age 60+) with fatty liver disease to find out what increases their risk for serious liver problems like scarring, cirrhosis, or liver cancer. Researchers used medical records and yearly check-ups to build a computer model that predicts th…

This study tested whether a mobile health app called EL-FIT could help people with nonalcoholic steatohepatitis (NASH) exercise safely at home. Seventeen adults with NASH used the app and a Fitbit to do daily exercise as they wished. The main goal was to see if it was feasible an…

This study examined medical records of 263 adults with NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. The goal was to identify which patients are at higher risk for advanced fibrosis. The findings may help doctor…

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…

This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…

This early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…

This study tested a new ultrasound feature that measures liver fat and compared it to the standard MRI method. About 60 adults with or at risk for fatty liver disease had two ultrasounds and one MRI. The goal was to see if the ultrasound could accurately estimate liver fat, which…

This early-stage trial tested the safety and tolerability of a single dose of J2H-1702 in 16 healthy women. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers measured how the body processes the drug and its effects, but t…

This study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. This is an early, first-in-human trial, so it focused only on safety …

This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with …